MedTrace Logo

Role of Microbiome in BCG Responsiveness Prediction

NCT05204199 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-04-05

No results posted yet for this study

Summary

Our primary aim is to investigate the use of microbial profile from the bladder and the feces of NMIBC patients as a predicting tool for therapy response prior to BCG administration.

Our second aim is to collect additional samples (blood, instrumented urine, bladder tissue, feces) to establish a local biobank for future microbiome projects.

Conditions

Sponsors & Collaborators

  • Krebsliga Schweiz

    collaborator UNKNOWN

  • Cédric Poyet

    lead OTHER

Principal Investigators

  • Cédric Poyed, MD · University Hospital Zurich, Departement of Urology

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2025-10-20
Completion
2025-10-20

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05204199 on ClinicalTrials.gov